The HS Code 29350032 refers to a specific classification used to identify and categorize the product Acetylsulfisoxazole; sulfacetamide, sodium; and sulfamethazine, sodium. This code is used internationally and helps facilitate trade by providing a standardized system for classifying goods.
Acetylsulfisoxazole; sulfacetamide, sodium; and sulfamethazine, sodium are pharmaceutical substances commonly used in the treatment of bacterial infections. Acetylsulfisoxazole is an antibiotic used primarily for urinary tract infections, while sulfacetamide, sodium is a topical antibiotic used for eye and skin infections. Sulfamethazine, sodium is another antibiotic used in the treatment of various bacterial infections.
The bound or MFN (Most Favored Nation) duty rate for HS Code 29350032 is 6.5%. This means that every time a country lowers a trade barrier or opens up a market, it must do so for the same goods or services from all its trading partners. This duty rate applies to imports of Acetylsulfisoxazole; sulfacetamide, sodium; and sulfamethazine, sodium.
The quantity unit for this HS Code is kilograms (KG). This unit of measurement is used to determine the weight or quantity of the product being imported or exported.
There are several special tariff preference programs applicable to HS Code 29350032. These programs provide preferential treatment in terms of duty rates for imports and exports of the product. The following countries and programs offer duty-free treatment for Acetylsulfisoxazole; sulfacetamide, sodium; and sulfamethazine, sodium:
When importing HS Code 29350032 into the United States, the following states are listed as importers:
On the other hand, the following states are listed as exporters of HS Code 29350032 from the United States:
The HS Code 29350032 provides a standardized classification for Acetylsulfisoxazole; sulfacetamide, sodium; and sulfamethazine, sodium, allowing for easier identification and tracking of the product in international trade. Understanding the HS Code and its associated duty rates and preferential treatment programs can help businesses navigate the global market more effectively.